Description
MubritinibisanEGFR2(HER2)inhibitorthatunderwentclinicaltrials,showingsomepromiseasananticancerchemotherapeuticinthetreatmentofbladder,kidney,andprostatecancer,butwasnotpursuedfurther.
MubritinibisanEGFR2(HER2)inhibitorthatunderwentclinicaltrials,showingsomepromiseasananticancerchemotherapeuticinthetreatmentofbladder,kidney,andprostatecancer,butwasnotpursuedfurther.
| CasNo. | 366017-09-6 |
|---|---|
| Purity | ≥98% |
| Formula | C25H23F3N4O2 |
| FormulaWt. | 468.47 |
| ChemicalName | 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole |
| IUPACName | 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole |
| Synonym | TAK-165 |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| MSDS | M8007MSDSPDF |
|---|---|
| InfoSheet | M8007InfoSheetPDF |
NagasawaJ,MizokamiA,KoshidaK,etal.NovelHER2selectivetyrosinekinaseinhibitor,TAK-165,inhibitsbladder,kidneyandandrogen-independentprostatecancerinvitroandinvivo.IntJUrol.2006May;13(5):587-92.PMID:16771730.